Vaccine Potential of Mycobacterial Antigens against Asthma

Mustafa, Abu Salim

doi:10.1159/000508719

Cited by 6 publications

(5 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This, along with the emergence of drug-resistant TB, has increased the necessity for developing a better vaccine for TB [ 9 ]. In addition, an effective vaccine against TB may also protect against asthma, another non-infectious disease of high global prevalence [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

An Overview of the Development of New Vaccines for Tuberculosis

2020

View full text Add to dashboard Cite

Currently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette–Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and causes complications in immunocompromised individuals. Furthermore, it compromises the use of antigens present in the purified protein derivate of Mycobacterium tuberculosis in the diagnosis of TB. Many approaches, e.g., whole-cell organisms, subunit, and recombinant vaccines are currently being explored for safer and more efficacious TB vaccines than BCG. These approaches have been successful in developing a large number of vaccine candidates included in the TB vaccine pipeline and are at different stages of clinical trials in humans. This paper discusses current vaccination strategies, provides directions for the possible routes towards the development of new TB vaccines and highlights recent findings. The efforts for improved TB vaccines may lead to new licensed vaccines capable of replacing/supplementing BCG and conferring therapeutic value in patients with active/latent TB.

show abstract

Section: Introductionmentioning

confidence: 99%

An Overview of the Development of New Vaccines for Tuberculosis

2020

View full text Add to dashboard Cite

show abstract

“…He worked on the TB vaccine with various international organizations. [25,[31][32][33] Haque, S., of the College of Nursing, Jazan University, KSA, is ranked second. He worked on evidence-based medicine related to TB and also drug-resistant M tuberculosis.…”

Section: Collaborative Research: Co-authorship Analysismentioning

confidence: 99%

Tuberculosis research advances and future trends: A bibliometric knowledge mapping approach

Abdelwahab,

Taha,

Albasheer

et al. 2024

Medicine

View full text Add to dashboard Cite

The Gulf Cooperation Council (GCC) countries are more vulnerable to many transmissible diseases, including tuberculosis (TB). This study is to identify the scientific publications related to TB in the GCC countries using topic modeling and co-word analysis. A bibliometric analytic study. The R-package, VOSviewer software, IBM SPPS, and Scopus Analytics were used to analyze performance, hotspots, knowledge structure, thematic evolution, trend topics, and inter-gulf and international cooperation on TB in the past 30 years (1993–2022). A total of 1999 publications associated with research on GCC-TB were published. The annual growth rate of documents was 7.76%. Saudi Arabia is the most highly published, followed by the United Arab Emirates, Kuwait, Qatar, Oman, and Bahrain. The most-cited GC country is Kingdom Saudi Arabia, followed by Kuwait. One hundred sixty research institutions contributed to the dissemination of TB-related knowledge in the GCC, where the highest publishing organizations were King Saud University (Kingdom Saudi Arabia; n = 518). The number of publications related to TB is high in GCC Countries. The current tendencies indicated that GCC scholars are increasingly focused on deep learning, chest X-ray, molecular docking, comorbid covid-19, risk factors, and Mycobacterium bovis.

show abstract

“…ESAT6-Like Proteins as a Subunit Vaccine against TB and Asthma ESAT6-like proteins have been evaluated as vaccines for protection against TB and asthma [10,52]. Multimeric DNA vaccine preparations containing ESAT6-family genes generated potent and broad antigen-specific T cell responses in mice as compared to vaccination with BCG [52].…”

Section: Esat6-like Proteins As Vaccines Formentioning

confidence: 99%

“…These studies suggest that the type of immune response induced by infection with M. tuberculosis or vaccination with Mycobacterium bovis BCG is protective against asthma. Hence, it is considered important to identify mycobacterial antigens that induce Th1 responses and can prevent both TB and asthma [10, 11].…”

Section: Introductionmentioning

confidence: 99%

Chemical and Biological Characterization of Mycobacterium tuberculosis-Specific ESAT6-Like Proteins and Their Potentials in the Prevention of Tuberculosis and Asthma

Mustafa

2023

Med Princ Pract

View full text Add to dashboard Cite

Early Secreted Antigenic Target 6 kDa (ESAT6) is a potent immunogenic protein secreted by the bacteria causing tuberculosis, i.e., Mycobacterium tuberculosis. Another highly immunogenic culture filtrate protein whose gene is linked to ESAT6/ESXA is known as CFP10/ESXB. Because of their high immunogenicity and specificity to M. tuberculosis, these proteins have been proposed as a vaccine to prevent tuberculosis and diagnose the active/latent disease. However, the same proteins cannot be used for prevention and diagnosis because immunized but healthy people will also show a positive response and be falsely reported as diseased. Therefore, in this review article, the search was made to identify if any other ESAT6-like proteins exist in the M. tuberculosis genome. The search identified 21 additional ESAT-like proteins, i.e., ESXC to ESXW. Immunological characterization has shown that some of them (especially ESXV) were able to induce immune responses in vitro with cells obtained from tuberculosis patients and healthy donors. When the protein ESXV was tested in different recombinant forms (expressed in Escherichia coli, mycobacterial vectors, and DNA plasmids) and injected in mice, immune responses were induced to multiple epitopes of the protein. Furthermore, immunization of mice with ESXV protected them from infection with M. tuberculosis. The same protein was also able to protect mice against the induction of asthma. These results suggest that ESXV has the potential to protect against two major diseases of the world, i.e., tuberculosis and asthma, and hence may be used as a common vaccine for both diseases.

show abstract

Vaccine Potential of Mycobacterial Antigens against Asthma

Cited by 6 publications

References 75 publications

An Overview of the Development of New Vaccines for Tuberculosis

An Overview of the Development of New Vaccines for Tuberculosis

Tuberculosis research advances and future trends: A bibliometric knowledge mapping approach

Chemical and Biological Characterization of Mycobacterium tuberculosis-Specific ESAT6-Like Proteins and Their Potentials in the Prevention of Tuberculosis and Asthma

Contact Info

Product

Resources

About